Insider Buying: Knight Therapeutics Inc. (TSE:GUD) Director Acquires C$103,000.00 in Stock

Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia purchased 20,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was acquired at an average price of C$5.15 per share, for a total transaction of C$103,000.00.

Knight Therapeutics Stock Performance

Shares of GUD opened at C$5.15 on Thursday. The company has a 50-day moving average of C$5.72 and a two-hundred day moving average of C$5.74. The stock has a market cap of C$521.23 million, a price-to-earnings ratio of -25.75, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. Knight Therapeutics Inc. has a one year low of C$5.07 and a one year high of C$6.23.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Stifel Nicolaus upgraded shares of Knight Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th. Stifel Canada raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.